News

 
News

 
January 13,2023 
Please Join ABio-X CEO Jeff Jonas and various industry experts on Wednesday, January 18th, from 2 to 3 p.m. ET as we look at what’s to come for the biotech sector in 2023. Take a look at some of the questions we’ll be debating below: Will pharmaceutical companies take a more active role in dealmaking? 
What clinical trial readouts could shape R&D investments?
Will demand for IPOs bounce back?
Save your free seat today: https://dive.pub/3vG0QatABio-X:Overview | LinkedIn

April 6, 2022
ENSEM Therapeutics is proud to announce our Series A funding of $67 million to further advance our Kinetic EnsembleTM platform and accelerate R&D pipeline.
Read more 

April 28, 2021Adcentrx Therapeutics Announces Completion of $50M Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development. 
Read more

January 13,2023

Please Join ABio-X CEO Jeff Jonas and various industry experts on Wednesday, January 18th, from 2 to 3 p.m. ET as we look at what’s to come for the biotech sector in 2023. Take a look at some of the questions we’ll be debating below:

Save your free seat today: https://dive.pub/3vG0Qat

ABio-X:Overview | LinkedIn

April 6, 2022ENSEM Therapeutics is proud to announce our Series A funding of $67 million to further advance our Kinetic EnsembleTM platform and accelerate R&D pipeline.Read more

April 28, 2021

April 6, 2022
ENSEM Therapeutics is proud to announce our Series A funding of $67 million to further advance our Kinetic Ensemble^TM platform and accelerate R&D pipeline.
Read more